This article is more than 5 years old. Information may no longer be current.

Early trial results look promising for drug for retinal detachment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — Results from a phase 1/2 trial to treat patients with rhegmatogenous retinal detachment show the intravitreal drug to be well tolerated at all doses tested and without serious adverse events, according to the drug's developer.

Inspire Pharmaceuticals noted results from a trial of its INS37217 Ophthalmic single-dose intravitreal injection drug indicated patients also showed improvement in the extent of retinal re-attachment. Patients treated with placebo showed no improvement, the company added.

The study was a randomized, placebo-controlled, double-masked dose-escalation comparison of INS37217 to placebo. Both compounds were delivered by intravitreal injection. Fourteen patients were enrolled in the study, according to Inspire.

INS37217 is a P2Y receptor agonist shown to stimulate the removal of accumulated fluid in the sub-retinal space, according to an Inspire news release.